# Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

> **NCT04322227** · PHASE1 · TERMINATED · sponsor: **H. Lundbeck A/S** · enrollment: 6 (actual)

## Conditions studied

- Parkinson Disease
- Healthy

## Interventions

- **DRUG:** Foliglurax 10 mg (treatment A)
- **DRUG:** Foliglurax 30 mg (treatment B)
- **DRUG:** Placebo (treatment C)

## Key facts

- **NCT ID:** NCT04322227
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-23
- **Primary completion:** 2020-05-30
- **Final completion:** 2020-05-30
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study termination due to efficacy results of another study
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04322227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04322227, "Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04322227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*